NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is a single center, non-blinded, multi-cohort, non-comparative phase II trial to study the safety and efficacy of tiragolumab with atezolizumab and/or ipilimumab in advanced triple-negative breast cancer.
Epistemonikos ID: 251520aeda9c6802b9aca69f39ad54d0b616d20a
First added on: May 15, 2024